ESR1 and triple-negative breast carcinoma: Abazid et al. found that ENZ treatment could decrease the expression level of the estrogen receptor in PCa, and the estrogen receptor increased ENZ sensitivity to AR (+) triple-negative breast cancer [44, 45].